Question 1

Am I eligible for this trial based on my current vision and diabetes management?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Study of Intravitreal Aflibercept Injection (IAI; EYLEA®; BAY86-5321) in Patients With Diabetic Macular Edema clinical trial (NCT01363440). Contact the study team or your healthcare provider for specific answers.

Question 2

How does the Aflibercept injection compare to other treatments I might consider?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Study of Intravitreal Aflibercept Injection (IAI; EYLEA®; BAY86-5321) in Patients With Diabetic Macular Edema clinical trial (NCT01363440). Contact the study team or your healthcare provider for specific answers.

Question 3

What are the potential side effects of the Aflibercept injection?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Study of Intravitreal Aflibercept Injection (IAI; EYLEA®; BAY86-5321) in Patients With Diabetic Macular Edema clinical trial (NCT01363440). Contact the study team or your healthcare provider for specific answers.

Question 4

How often would I need to come in for treatment and monitoring if I participate?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Study of Intravitreal Aflibercept Injection (IAI; EYLEA®; BAY86-5321) in Patients With Diabetic Macular Edema clinical trial (NCT01363440). Contact the study team or your healthcare provider for specific answers.

Question 5

What happens if I experience any complications during the trial?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Study of Intravitreal Aflibercept Injection (IAI; EYLEA®; BAY86-5321) in Patients With Diabetic Macular Edema clinical trial (NCT01363440). Contact the study team or your healthcare provider for specific answers.

Question 6

Can you explain how this treatment might fit into my overall diabetes care plan?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Study of Intravitreal Aflibercept Injection (IAI; EYLEA®; BAY86-5321) in Patients With Diabetic Macular Edema clinical trial (NCT01363440). Contact the study team or your healthcare provider for specific answers.

What this study is about